Targeting melanoma cells through G-quadruplex formation: Mechanism and enhanced efficacy of T-oligo in combination therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need ...
This review systematically summarizes the research progress in Polyphenol self-assembled drug delivery systems (DDS), with a focused elaboration on their assembly mechanisms, functional advantages ...
- Publication describes how the unique qualities of ARCUS nucleases contribute to precise and efficient gene editing for gene insertion, single base editing, specific small and large deletions, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results